4.23
+0.15(+3.68%)
Currency In USD
| Previous Close | 4.08 |
| Open | 4.02 |
| Day High | 4.28 |
| Day Low | 3.96 |
| 52-Week High | 20.21 |
| 52-Week Low | 3.61 |
| Volume | 831,648 |
| Average Volume | 960,058 |
| Market Cap | 153.29M |
| PE | -1.05 |
| EPS | -4.01 |
| Moving Average 50 Days | 8.18 |
| Moving Average 200 Days | 8.96 |
| Change | 0.15 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $227.42 as of December 21, 2024 at a share price of $4.23. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 2 years ago, it would be worth $502.38 as of December 21, 2024 at a share price of $4.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
GlobeNewswire Inc.
Dec 17, 2024 1:10 PM GMT
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achieved in target, beta-cell deficient patients on one
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
GlobeNewswire Inc.
Dec 16, 2024 11:15 PM GMT
Tuesday, December 17, 2024 at 8:00 am ESTREDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small m
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
GlobeNewswire Inc.
Dec 12, 2024 10:02 PM GMT
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels of both the GLP-1 receptor (GLP-1R) as well as int